Evergreen Talk Series: Clinical Considerations for Linagliptin and its combinations with Metformin, Dapagliflozin

Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an Interventional Cardiologist from Ahmedabad, and Dr. Tukaram Jamale, a Nephrologist and Kidney Transplant Physician who serves as the Head of the Department at KEM Hospital Mumbai. They provide their insights on the use of Linagliptin, Dapagliflozin, and Metformin for diabetic patients.

Bringing viewpoints from the different specialities of Diabetology, Cardiology and Nephrology they share the Clinical Considerations for Linagliptin and its combinations with Metformin and Dapagliflozin

Dr Brij Mohan Makkar: The advantage of having a Fixed-Dose Combination (FDC) is improved compliance, making therapy more effective. Now, when it comes to the use of combinations, I think there is hardly any scenario where I do not use the combination of Linagliptin and Metformin. In my practice, I am more aggressive and frequently use a combination of Metformin, DPP4, and SGLT2 inhibitors to begin with. The only scenarios where I would not use this combination are if there is any hypersensitivity to any of these molecules or if the patient is very elderly and frail, in which case, I refrain from using the initial combination of Metformin, DPP4, and SGLT2 inhibitors